Biotechnology · Healthcare
CEO
Equibles does not estimate personal net worth.
Get an email with a short summary when Jade Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get JBIO alertsTom Froelich is recorded as CEO at Jade Biosciences, Inc. (JBIO). Tom Froelich has spoken on 5 investor events across 1 company, most recently for Jade Biosciences, Inc. on November 17, 2026. Jade Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jade Biosciences, Inc. includes Tom Frohlich (CEO and Board Member), Eric Dobmeier (Chairman and Board Member), Bradford Dahms (CFO) and 7 others.
“We're a company focused on developing best-in-class therapies across a number of different autoimmune diseases. Our lead program is Jade 101. It's an anti-April therapy targeting IgA nephropathy at the outset.”
“We're a company developing best-in-class assets across a number of different autoimmune disorders. As Mike pointed out, our lead program is Jade 101, which is a selective anti-April inhibitor.”
“And first of all, just thanks Arthur for hosting us here at the conference. It's been a great couple of days. So thanks to you and the whole H.C. Wainwright team.”
“Before we get into Q&A, I'll hand it over to you for any opening remarks great thanks so much and thanks to you and the whole team for for hosting us it's been a really pretty get a chance to get back into the season after an amazing summer yeah really pleased to talk a little bit about about Jade or a fairly new…”
“I did want to just take a moment actually to thank the team at Bloom Burton. This is actually one of my favorite conferences of the entire year.”
Biotechnology · Healthcare
CEO